Wirkungen
„Anti-cancer effects“ wurden in Studien in vitro und oder in vivo nachgewiesen gegen:
- Leukämie
- Brustkrebs
- Dickdarmkrebs
- Gebärmutterhalskrebs
- Lungenkrebs
- Osteosarkom
The anti-microbial effect of SCL against Candida yeasts, including C. albicans, C. glabrata, C. parapsilosis, and C. tropicalis was almost equivalent to Fluconazole (Popova et al., 2019).
SCL also exerted antifungal synergies with Curcumin towards various fungus, including Candida albicans, C. glabrata, Aspergillus fumigatus (Augostine and Avery, 2022). The derivates of SCL were reported more effective against plant pathogenic fungal A. alternate and A. brassicae than thiabendazole (Ma et al., 2018).SCL was first reported to inhibit helminth growth in larval (IC50 ≈ 13 μm), juvenile (IC50 = 5.0 μm), and adult (IC50 = 19.3 μm) stages of Schistosoma mansoni, a pathogen of schistosomiasis. Among 14 derivates of SCL, the most effective compound 12 enhanced cytoxicity against larval (IC50 ≈ 2.2 μm), juvenile (IC50 = 1.7 μm), and adult schistosomes (IC50 = 9.4 μm) by interfering with arachidonic acid metabolism to regulate membrane lipid homeostasis (Crusco et al., 2019). Importantly, the wide-spectrum effect against filoviruses of SCL has been proposed, especially, SCL was considered as Ebola virus (EBOV) entry inhibitor by interfering the viral fusion process (EC50 = 2.4 μm) (Chen Q. et al., 2020). In antibiotic resistance, SCL performed synergistic effect with clindamycin against Methicillin-resistant Staphylococcus aureus (Iobbi et al., 2021). SCL also exerted antifungal synergies with Curcumin towards various fungus, including Candida albicans, C. glabrata, Aspergillus fumigatus (Augostine and Avery, 2022). The derivates of SCL were reported more effective against plant pathogenic fungal A. alternate and A. brassicae than thiabendazole (Ma et al., 2018).
In antibiotic resistance, SCL performed synergistic effect with clindamycin against Methicillin-resistant Staphylococcus aureus (Iobbi et al., 2021).
Importantly, the wide-spectrum effect against filoviruses of SCL has been proposed, especially, SCL was considered as Ebola virus (EBOV) entry inhibitor by interfering the viral fusion process (EC50 = 2.4 μm) (Chen Q. et al., 2020).
SCL was first reported to inhibit helminth growth in larval (IC50 ≈ 13 μm), juvenile (IC50 = 5.0 μm), and adult (IC50 = 19.3 μm) stages of Schistosoma mansoni, a pathogen of schistosomiasis. Among 14 derivates of SCL, the most effective compound 12 enhanced cytoxicity against larval (IC50 ≈ 2.2 μm), juvenile (IC50 = 1.7 μm), and adult schistosomes (IC50 = 9.4 μm) by interfering with arachidonic acid metabolism to regulate membrane lipid homeostasis (Crusco et al., 2019).
The reduction of blood pressure SCL induced was observed in normotensive and hypertensive rats, the phenomenon was probably due to ameliorated vasodilation via NO/cGMP signaling (Campos et al., 2017). The regulation of blood pressure mediated by SCL indicates it may be applied to cardiovascular disease as potential hypotensor. In addition, SCL was viewed as one of the bioactive components in Salvia miltiorrhiza and Dalbergia odorifera against miocardial infarction (Zhao et al., 2022)
SCL improved hyperglycemia-induced renal injury (renal dysfunction, fibrosis, and inflammation) to prevent diabetic nephropathy through inducing inactivation of MAPKs and NF-κB pathway (Han et al., 2022).
SCL was considered as candidate drug to treat or prevent SARS-CoV-2 via targeting Covid19 Main Protase (MPro) (Aydın et al., 2021)
SCL was identified as a novel Cav1.3 antagonist against Parkinson’s disease (Wang et al., 2022).
Sclareol as F1Fo-ATP synthase inhibitor restrained free radical production in the retinal rod, which indicated SCL could serve as a potential drug for retinal disease (Ravera et al., 2020).